Lucid Diagnostics Inc. (LUCD): Nasdaq/NYSE listing notice — Lucid Diagnostics transfers Nasdaq listing to Capital Market after Global Market non-compliance

Lucid Diagnostics Inc.

Received Nasdaq approval on Nov 27, 2023 to transfer common stock listing from Global Market to Capital Market.
Transfer effective Nov 29, 2023; trading symbol LUCD unchanged.
Company was not in compliance with Equity standard for continued listing on Nasdaq Global Market.
Company meets continued listing standards for Nasdaq Capital Market, resolving the deficiency.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Lucid Diagnostics Inc. received a nasdaq deficiency notice notice regarding market value.

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value

Exact text from the filing

received a notice from the Nasdaq Listing Qualifications Department stating that the Company was no longer in compliance with the Equity standard for continued listing on the Nasdaq Global Market (and that the Company did not meet the alternative standards for Market Value or Total Assets/Total Revenue). Upon the transfer of the listing of the Company’s common stock to the Nasdaq Capital Market, this deficiency will be resolved because the Company presently meets the continued listing standards for the Nasdaq Capital Market.

View on SEC.gov

Browse all listing & compliance notices →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-042922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.